Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated subcutaneous ketamine for major depressive disorder
ACTRN12616001096448Phase 3Completed
- Sponsor
- University of New South Wales
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by University of New South Wales. Primary endpoint: Remission at end of randomized controlled phase. Started Aug 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12616001096448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001096448.